Get the Stockscreener App
442.00
0.27%
-1.18
Pre-market:
442.00
Madrigal Pharmaceuticals Inc stock is traded at $442.00, with a volume of 314.91K.
It is down -0.27% in the last 24 hours and down -10.07% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$443.18
Open:
$440
24h Volume:
314.91K
Relative Volume:
0.93
Market Cap:
$10.14B
Revenue:
$958.40M
Net Income/Loss:
$-288.28M
P/E Ratio:
-34.36
EPS:
-12.8641
Net Cash Flow:
$-193.02M
1W Performance:
+2.43%
1M Performance:
-10.07%
6M Performance:
+0.28%
1Y Performance:
+30.56%
1-Day Range:
$427.76
$446.18
1-Week Range:
$421.55
$455.00
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
442.00 | 10.14B | 958.40M | -288.28M | -193.02M | -12.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal grants inducement awards to five employees - MSN
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN
Madrigal slides more than 5% as wider Q4 loss tempers strong sales growth - MSN
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY - MarketBeat
Iron Triangle Partners LP Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
First Light Asset Management LLC Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Baker BROS. Advisors LP - MarketBeat
32,662 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Ally Bridge Group NY LLC - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ArrowMark Colorado Holdings LLC - MarketBeat
120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC - MarketBeat
Madrigal Pharmaceuticals presence at Liver Connect Conference as attendance doubles - Traders Union
Avoro Capital Advisors LLC Cuts Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Is Rezdiffra’s Near‑US$1 Billion Debut Reshaping The Investment Case For Madrigal Pharmaceuticals (MDGL)? - simplywall.st
Connor Clark & Lunn Investment Management Ltd. Reduces Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Pullback - simplywall.st
Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
Madrigal Pharmaceuticals Grants Equity Awards to 20 New Employees - MyChesCo
Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge? - Yahoo Finance
2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy - Finviz
Fieldview Capital Management LLC Invests $2.14 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Discipline and Rules-Based Execution in MDGL Response - Stock Traders Daily
Rhenman & Partners Asset Management AB Purchases Shares of 18,250 Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Madrigal Pharmaceuticals EVP Dier sells $854k in stock - Investing.com
Madrigal Pharmaceuticals EVP Dier sells $854k in stock By Investing.com - Investing.com South Africa
Pharma News: Why Madrigal Pharmaceuticals Inc. stock could be next big winnerTrade Volume Report & High Accuracy Swing Entry Alerts - Naître et grandir
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Sells $853,984.34 in Stock - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells $718,316.22 in Stock - MarketBeat
Market Review: Why Madrigal Pharmaceuticals Inc. stock could be next big winnerPortfolio Update Summary & Stock Timing and Entry Methods - Naître et grandir
Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Sells $155,498.40 in Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells 491 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals CEO Sibold sells $718k in shares By Investing.com - Investing.com Canada
Madrigal (NASDAQ: MDGL) CFO sells stock and gets new equity grants - Stock Titan
Madrigal Pharmaceuticals general counsel sells $155k in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals CEO Sibold sells $718k in shares - Investing.com
[144] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal Pharmaceuticals (MDGL) GC gets equity grants and tax sale - Stock Titan
Madrigal (NASDAQ: MDGL) CCO logs tax sale and new equity grants - Stock Titan
Carole Huntsman to sell 419 shares — Madrigal (NASDAQ: MDGL) Form 144 - Stock Titan
Insider sales by Madrigal (MDGL) include 24,800 and 18,650-share trades - Stock Titan
Madrigal Pharmaceuticals (MDGL) reports record 2025 revenue driven by Rezdiffra success - MSN
Teachers Retirement System of The State of Kentucky Invests $1.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal gains after Rezdiffra patent win - MSN
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):